Weekly Digest – August 2024 Weekly Digest – August 2024 19 Aug 2024: ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer ENHERTU® has been granted Breakthrough Therapy Designation in the U.S. […]
Weekly Digest – August 2024 Weekly Digest – August 2024 19 Aug 2024: ENHERTU® Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine Therapy The European Medicines […]
Weekly Digest – August 2024 Weekly Digest – August 2024 12 Aug 2024: Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 Alphamab Oncology will present new data on JSKN003 at […]
Weekly Digest – August 2024 Weekly Digest – August 2024 13 Aug 2024: First patient dosed with ADC therapy designed to disrupt tumor blood supply Angiex has initiated the first-in-human trial of AGX101, an antibody-drug conjugate (ADC) designed to target […]
Weekly Digest – August 2024 Weekly Digest – August 2024 13 Aug 2024: Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in […]
Weekly Digest – August 2024 Weekly Digest – August 2024 15 Aug 2024: ArriVent licenses ADC from $100M biobuck deal with Aarvik ArriVent BioPharma has licensed an antibody-drug conjugate (ADC) from Aarvik Therapeutics, following a $100 million deal from December […]
Weekly Digest – August 2024 Weekly Digest – August 2024 12 Aug 2024: Mabwell’s Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China’s NMPA Mabwell’s novel Nectin-4 targeting antibody-drug conjugate (ADC), 9MW2821, has received Breakthrough Therapy Designation from […]
Weekly Digest – August 2024 Weekly Digest – August 2024 07 Aug 2024: Invenra Highlights Exelixis’ Announcement: Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors Exelixis has started the dose-escalation stage of a Phase […]
Weekly Digest – August 2024 Weekly Digest – August 2024 07 Aug 2024: Daiichi Sankyo and MSD expand collaboration on ADC development Daiichi Sankyo and MSD have expanded their partnership to globally develop and commercialize three DXd antibody-drug conjugates, including […]
Weekly Digest – August 2024 Weekly Digest – August 2024 07 Aug 2024: Exelixis drops tissue factor-targeting ADC after deciding it’s no match for Tivdak Exelixis has decided to discontinue development of its tissue factor-targeting antibody-drug conjugate, XB002, after assessing […]
